UROLOGY - ORIGINAL PAPER



Prevalence of pediatric lower urinary tract symptoms in a national claims database of privately insured patients, 2003–2014

Kathleen M. Kan¹ · Gunjan Agrawal² · Raphael Brosula¹ · Pranaya Venkatapuram¹ · Abby L. Chen¹ · Chiyuan A. Zhang¹

Received: 20 October 2023 / Accepted: 5 December 2023 / Published online: 30 January 2024 © The Author(s), under exclusive licence to Springer Nature B.V. 2024

Abstract

Background We conducted this study to estimate the prevalence of pediatric lower urinary tract symptoms (pLUTS) in a US privately insured pediatric population who are 6–20 years old by age, sex, race/ethnicity from 2003–2014. This has not been previously described in the literature.

Methods We retrospectively reviewed Optum's de-identified Clinformatics® Data Mart Database between 2003–2014. A pLUTS patient was defined by the presence of ≥ 1 pLUTS-related ICD-9 diagnosis code between the age of 6–20 years. Neurogenic bladder, renal transplant and structural urologic disease diagnoses were excluded. Prevalence by year was calculated as a proportion of pLUTS patients among the total population at risk. Variables reviewed included age, sex, race, geographic region, household factors and clinical comorbidities including attention-deficit/hyperactivity disorder (ADHD), constipation, and sleep apnea. Point of service (POS) was calculated as a proportion of pLUTS-related claims associated with a POS compared to the total claims at all POS in the time period.

Results We identified 282,427 unique patients with ≥ 1 claim for pLUTS between the ages of 6–20 years from 2003 to 2014. Average prevalence during this period was 0.92%, increasing from 0.63% in 2003 to 1.13% in 2014. The median age group of patients was 6–10 years. More patients were female (59.80%), white (65.97%), between 6 and 10 years old (52.18%) and resided in the Southern US (44.97%). Within a single household, 81.71% reported ≤ 2 children, and 65.53% reported ≥ 3 adults. 16.88% had a diagnosis of ADHD, 19.49% had a diagnosis of constipation and 3.04% had a diagnosis of sleep apnea. 75% of pLUTS-related claims were recorded in an outpatient setting.

Conclusions Families consistently seek medical care in the outpatient setting for pLUTS. The demographic and clinical characteristics of our cohort reflect prior literature. Future studies can help define temporal relationships between house-hold factors and onset of disease as well as characterize pLUTS-related healthcare resource utilization. Additional work is required in publicly insured populations.

Keywords Lower urinary tract symptoms · Population health research · Pediatrics

Abbreviations

Kathleen M. Kan kkan@stanford.edu

¹ Department of Urology, Stanford University School of Medicine, 453 Quarry Road, Urology 5656, Palo Alto, CA 94304, USA

² Flushing Hospital Medical Center, 4500 Parsons Blvd, Flushing, NY 11533, USA

HCUP	Healthcare utilization project
DUI	Daytime urinary incontinence
CDM database	Clinformatics® Data Mart
ER	Emergency room
LUTD	Lower urinary tract dysfunction

Introduction

Pediatric lower urinary tract symptoms (pLUTS) has remained a collection of common childhood conditions in the United States. pLUTS includes a range of presentations in children older than 5 years who have completed potty training, such as daytime and nighttime incontinence, urgency, frequency, and dysuria [1]. Factors associated with disease presentation include gender, family history of incontinence, constipation and behavioral disorders such as attention-deficit/hyperactivity disorder (ADHD) [2–4]. Sequelae of disease includes decrease in quality of life and self-esteem as well as recurrent urinary tract infection [5, 6].

An estimated 36–128 million dollars/year are spent on pediatric incontinence using Healthcare Cost and Utilization Project (HCUP) data [7]. Data estimating prevalence of pLUTS has largely relied on cross-sectional survey methods. Three large studies found daytime urinary incontinence (DUI) in 10% of children sampled, though differences in study techniques and questionnaires limits direct comparison of findings [8–10]. pLUTS symptoms within these DUI populations were higher with participants reporting urgency, frequency and voiding postponement behaviors [8–10].

The number of children with pLUTS seeking medical care and how they use medical resources has not been welldefined. Existing HCUP data estimates a rate of approximately 1000 per 100,000 children ages 3–10 years requiring outpatient care for a diagnoses of pediatric incontinence per year [7]. No data exists on additional drivers of healthcare utilization such as household factors or clinical co-morbidities. In order to understand disease burden, longitudinal risk factors, and design effective population-level treatment strategies, it is necessary to further characterize this patient population.

Optum's de-identified Clinformatics[®] Data Mart Database (hereafter, referred to as CDM database) is a US database with pharmaceutical and health claims of commercially insured individuals across all 50 states. Both the pediatric population and outpatient setting are represented. Results may be limited by differences in population characteristics in a commercially insured versus uninsured group, however, this dataset still represents a unique opportunity to explore a pLUTS cohort using claims data that can be used for future healthcare resource utilization studies. We aim to define the prevalence of individuals with pLUTS who are seeking medical care from 2004 to 2014 within the CDM database, and characterize point of service (POS), demographic factors and clinical comorbidities of constipation and ADHD within this cohort.

Methods

Data source

After obtaining institutional review board approval, we analyzed data derived from the CDM database between the years 2003–2014. CDM database is a de-identified database derived from a large adjudicated claims data warehouse. It includes deidentified administrative health claims

for members of large commercial and Medicare Advantage health plans, with approximately 15–20 million annual covered lives. Enrollment, demographic and healthcare claims data related to outpatient services and emergency room visits are available. Diagnoses were coded using the International Classification of Diseases, ninth revision (ICD-9), procedures using Current Procedural Terminology (CPT).

Study population

We conducted a retrospective population-based cohort study. Our cohort included all patients ages 6-20 years old at any time between 2003 and 2014 with an ICD-9 code for pLUTS (Appendix) similar to prior HCUP data [7]. A patient was considered to have pLUTS if they had ≥ 1 diagnosis associated with any POS claim (i.e., POS claim associated with an inpatient, outpatient, or emergency room visit). We excluded patients with an ICD-9 diagnosis or CPT surgical code related to neurogenic bladder, renal transplant and structural urologic disease that increases risk for pLUTS-hypospadias, vesicoureteral reflux, posterior urethral valves, urethral stricture disease and ureterocele. The total population at risk per year between the ages 6-20 years old in the database was obtained from CDM database member data files version 7.0. To analyze demographic and clinical characteristics, we included all patients 6-20 years old at any time between 2003 and 2014 with an ICD-9 code for pLUTS.

Daytime and nighttime incontinence were defined by ICD-9 codes specific to incontinence. The remaining non-incontinence codes were grouped together as "other pLUTS." Patient demographics, including age, sex, race, and clinical comorbidities, were collected. The primary outcome was prevalence of pLUTS per 1 year period between 2003 and 2014. Secondary outcomes were characterization of point of service, demographic variables and clinical characteristics within the pLUTS population over the total time period. Demographic variables included age, race, geographic region, household income level of primary insurance provider and number of household members. Clinical comorbidities included constipation and ADHD as defined by ICD-9 codes at any point in time (Appendix).

Statistical analysis

Prevalence of pLUTS by year was calculated as a proportion of pLUTS patients among the total population at risk within a 6–20 year age group per each one-year period. Each pLUTS patient was counted once per year and could be counted the following year until they reached 20 years of age or left the database. Descriptive analysis of demographic characteristics and clinical comorbidities within the total pLUTS population were calculated as percentages over the total time period. All analysis was conducted using Excel, and descriptive summaries were obtained within Redivis.

Results

We identified the total population at risk during this time period to be 9,263,933. After applying exclusion criteria, our total pLUTS cohort was 282,427. This data demonstrates a 0.92% average prevalence of pLUTS between 2003 and 2014. Yearly prevalence increased from 0.63% in 2003 to 1.13% in 2014 (Fig. 1). Among patients who visited a medical facility for a pLUTS related diagnosis, office visits comprise the majority of total clinical encounters (59.70%), followed by outpatient hospital visits (15.27%), inpatient hospitalization (3.50%), and emergency room (ER) visits (2.16%) (Table 1).

The median age group of patients was 6–10 years with the highest proportion of patients also in this age group (147,362, 52.18%). The majority of patients were female (59.80%), white (65.97%), and from the South (44.97%). Most families reported a household income > 40 k (45.47%) however we noted a 74% fill rate in this data. Among all households, 81.71% reported \leq 2 children. 65.53% of households reported \geq 3 adults. Daytime (28.33%) and nighttime (22.23%) incontinence diagnoses made up 50.56% of ICD-9 codes. Among all patients with pLUTS, 34.06% had a relevant clinical comorbidity. Of these diagnoses, constipation was the most common (19.49%), followed by ADHD (16.88%) (Table 1).

Discussion

Average prevalence of pLUTS necessitating medical care in the CDM Database was found to be 0.92%, increasing from 0.63% in 2003 to 1.13% in 2014. We demonstrate the degree to which pLUTS burden is largely centered around outpatient care services (77.13%) compared to inpatient or emergency room visits. Most patients were younger, female and resided in the Southern US. ADHD and constipation rates mirror existing literature [22].

Prevalence of pLUTS in the global community has been measured via cross-sectional survey methods. Chung et al. found "dysfunctional voiding" symptoms in 46.4% of Korean children ages 5–13 [9]. Type of presentations varied—16.8% demonstrated urge incontinence, 16.6% urgency alone, 11.2% DUI, and 5.6% NE [9]. Lower urinary tract dysfunction (LUTD) was found in 9.3% of Turkish schoolchildren ages 6–15 years old and [10] 21.8% of Brazilian children [11]. Differences in prevalence can be attributed to differences in study population, age groups and type of survey administered (validated vs non-validated) along respondent bias. Our use of a claims database relies on clinical assessment with rates less likely to be affected by factors such as likeliness to self-report, survey response rates and recall bias.

An overall prevalence of 0.92% in the CDM database represents the percentage of privately insured pediatric patients seeking treatment for pLUTS. This prevalence is similar to rates seen in HCUP data of approximately 1,000 out of every 100,000 families seeking care for pediatric incontinence in age groups 3–10 years old within a year [7]. As expected, this number is lower than overall community prevalence estimates, as only 10–16% of families may seek medical care [12]. While severity and frequency may be related to this decision, in a population-based cross-sectional study




Fig. 1 Prevalence by year of pLUTS from 2003–2014

 Table 1 Descriptive statistics of demographics, socioeconomic variables, comorbidities, and treatment among total number of unique pLUTS patients

Variables	Ν	Percentage
Total number of unique pLUTS patients	282,427	
Age		
6–10	147,362	52.18
11–15	58,257	20.63
16–20	76,808	27.20
Sex		
Male	113,493	40.18
Female	168,882	59.80
Unknown	52	0.02
Region		
Northeast	28,769	10.19
Midwest	96,774	34.27
South	127,002	44.97
West	48,668	17.23
Unknown	1,043	0.37
Race		
White	186,324	65.97
Hispanic	20,290	7.18
Black	21,327	7.55
Asian	6,926	2.45
Unknown	47,560	16.84
Household income		
<\$40 k	18,013	6.38
>\$40 k	128,429	45.47
Unknown	135,985	48.15
Fed poverty level		
Below (below 400 FPL)	1,387	0.49
Above (above 400 FPL)	145,055	51.36
Unknown	135,985	48.15
Number of children in household		
≤ 2	230,776	81.71
>2	11,932	4.22
Unknown	39,719	14.06
Number of adults in household		
≤ 2	57,620	20.40
>2	185,088	65.53
Unknown	39,719	14.06
Comorbid conditions		
ADHD	47,671	16.88
Constipation	55,052	19.49
Type of pLUTS		
Daytime incontinence	80,000	28.33
Nighttime incontinence	62,771	22.23
Other pLUTS	185,059	49.63
Point of service		
Total	27,327,388	100.00
Office	16,315,921	59.70
Outpatient hospital	4,174,574	15.27

Table 1	(continued)	
---------	-------------	--

Variables	N	Percentage
Inpatient hospital	956,959	3.50
Emergency room	591,096	2.16
Unknown	5,465,477	20.00

of children starting elementary school who experienced wetting daily, 40% had not received medical care [12, 13]. Additional drivers such as lack of access to care, lack of knowledge regarding treatment options, or social norms that pLUTS is a condition to be outgrown, may play a role in treatment-seeking behaviors [13].

Of the total claims associated with a pLUTS diagnosis, 77.13% were performed in an outpatient setting. This is in contrast to the low numbers of patients requiring inpatient care (3.5%) for incontinence diagnoses, which reflect previously reported data for this point of service [7]. Our study found higher proportion of females (59%) and patients ages 6–10 years old (52.18%). While some studies have found a higher prevalence of LUTD and DUI in girls [13, 14], this has not been consistently demonstrated in other large studies [15].

Data from longitudinal studies of children with DUI found the highest prevalence of disease in early childhood with a spontaneous remission rate of 15.4% per year [16]. Yuksel et al. found that the rates of LUTD stabilized around the ages of 10 in girl and 11 in boys, potentially representing pubertal changes [10]. While the prevalence of disease in the community may drop in older children, we found that the next largest group of patients with pLUTS seeking medical care was 16 years or older (27%). This may reflect increased duration and/or severity of disease that prompts medical care or increasing independence in social activities that increases degree of bother.

Treatment of pLUTS consists of behavioral and lifestyle modifications to improve voiding, stooling and hydration habits. Effective application and adherence to these changes may be influenced by social determinants of health including availability of healthy foods, housing factors, and access to healthcare and education. Other studies have shown that low levels of parental education, double-income families and household factors such as increased number of siblings or family members or increased number of people sleeping in the child's room, were more likely to have pLUTS. However, direct associations between low-income households, presence or absence of insurance have not been observed [9, 10, 17, 18]. Housing factors such as number of people per room or number of siblings may play a role in NE, potentially reflecting crowding at home that limits bathroom access. In our study, families with fewer children and >3 adults in the family had higher proportion of pLUTS diagnoses. This could represent lack of knowledge of pLUTS with fewer children, and household crowding factors, though this population generally fell above the federal poverty line.

Prevalence of constipation in the general population varies from 0.7 to 29.6% [19]. It is higher within the pLUTS population; 34% of children with constipation experience NE and 29% experience DUI [20]. The bladder and rectum are situated next to each other in the pelvis, sharing similar innervation for urethral and anal sphincter control and higher pelvic floor tone, leading to symptoms [21]. Children who have a large stool burden may develop a distended rectum that stimulates detrusor muscle contractions, experienced as pain, urgency, incontinence [21] and fear of painful elimination. We found that 19.49% of children in our pLUTS population had a diagnosis of constipation and a higher proportion of children with pLUTS were found in Southern US regions, where higher rates of constipation are observed [22]. This may reflect factors that link both presentations together, such as diet or water consumption, versus the above internal factors.

Behavioral problems, such as ADHD, are also comorbid with pLUTS presentations. Following a systematic review, an overall pooled estimate of ADHD prevalence in the community is 7.20% [23]. A study of > 8000 children found a nearly double rate of externalizing problems related to attention and activity problems, oppositional behavior and conduct disorders in children with DUI versus those without DUI [24]. In our cohort of children with pLUTS, 16.88% had a diagnosis of ADHD. This may be related to the secondary effects of wetting on the development of behavioral symptoms or psychological problems [24].

The rates of comorbid constipation and ADHD are important to note due to the potential for these patients to experience lower compliance and less successful outcomes with treatment outcomes. Specific outreach and education programs may be required to address additional needs within these children.

Our description of patients seeking medical care for their symptoms has limitations in its application to a national population. Claims databases are subject to inaccurate and/or missing data [25]. Our choice of pLUTS ICD codes is based on prior literature, however, sensitivity and specificity in the accuracy of coding has not been investigated for these diagnoses. To obtain a picture of healthy children seeking medical care for these diagnoses, we excluded clinical conditions such as transplant and neurogenic bladder, however, the role of additional conditions such as developmental delay and presence of absence of urinary tract infection were not investigated. Limitations of our cohort design include (1) an underestimate of the prevalence of pLUTS due to physicians' coding practices related to diagnostic sub-types of pLUTS and existing co-morbidities, and (2) the exclusion of patients

with conditions such as vesicoureteral reflux and UTI who may have an accompanying pLUTS diagnosis leading to an underestimation of disease burden. Additionally, we chose to present descriptive data of overall utilization as opposed to rates within subpopulations, which limits more specific interpretations of the data.

The CDM database is a national sample of patients who are privately insured. It therefore represents a subset of a much larger population, specifically families who may be overall healthier and able to seek medical care. While this limits generalizability, our research question benefits from this cohort since we assume this is closer to the maximum number of patients who would seek care as opposed to an underestimate due to poor access to education or healthcare resources.

Conclusion

In conclusion, a rate of approximately 1% annual prevalence of pLUTS in the CDM database points to a large and consistent burden to the healthcare system that would benefit from further studies. It is likely that the prevalence of pLUTS is underestimated here due to coding practice and, exclusion of patients with vesicoureteral reflux and UTI who may also have pLUTS. This could suggest that annual prevalence and associated burden could be greater than reported. An improved understanding of clinical and demographic risk factors for pLUTS using longitudinal study methods in a population with a broad range of insurance providers will help to inform effective treatment and prevention strategies. Further investigation into healthcare resource utilization using claims data will allow these programs to target areas of improvement to reduce healthcare spending and prompt investment into preventative programs.

Appendix

Description	ICD-9 code	Code description
pLUTS diagnosis codes		
pLUTS	307.6	Enuresis
	590.0	Chronic pyelonephritis without lesion of renal medullary
	595.0	Acute cystitis
	595.3	Trigonitis
	595.9	Cystitis, unspecified

Description	ICD-9 code	Code description	Description	ICD-9 code	Code description
	596.0	Bladder neck obstruction		966.81	Complications of trans-
596.51	Hypertonicity of bladder			planted kidney	
	599.0 Urinary tract int not specified	Urinary tract infection, site not specified	Urologic conditions Vesicoureteral reflux (VUR)	593.70	Vesicoureteral reflux,
	599.89	Other specific disorders of urinary tract			unspecified or without reflux nephropathy
	599.9	Unspecified disorder of urethra and urinary tract		593.71	Vesicoureteral reflux with reflux nephropathy, unilateral
	625.6	Stress incontinence (female)		593.72	Vesicoureteral reflux with
	788.1 788.21	Dysuria Incomplete bladder empty-		575.12	reflux nephropathy, bilateral
		ing		593.73	Other vesicoureteral reflux
	788.30	Urinary incontinence unspecified		0,0110	with reflux nephropathy NOS
	788.31	Urge incontinence	Ureterocele	753.23	Congenital ureterocele
	788.33	Mixed incontinence (male/ female)	Posterior urethral valves (PUV)	753.6	Atresia and stenosis of ure- thra and bladder neck
	788.34	Incontinence without sen- sory awareness	Hypospadias	58.45	Repair of hypospadias and epispadias
	788.35	Post-void dribbling	Description	CPT code	Code description
	788.36	Nocturnal enuresis	-		
	788.38	Overflow incontinence	Renal transplant	50360	Renal allotransplanta-
	788.39	Other Urinary Incontinence			tion; implementation of graft, excluding donor
	788.41	Urinary frequency			and recipient nephrec-
	788.62	Slowing of urinary stream			tomy (without recipient
	788.63	Urgency of urination		50265	nephrectomy)
	788.64	Urinary hesitancy		50365	Renal allotransplantation, implantation of graft; with
	788.65	Staining on urination			recipient nephrectomy
	788.69	Other abnormality of uri- nary stream/urination	Urologic conditions Vesicoureteral reflux	50660	Unstancetones, total estania
Comorbidities in pLUTS	S cohort		(VUR)	50660	Ureterectomy, total, ectopic ureter, combination
ADHD	314	Attention deficit disorder of childhood	(()))		abdominal, vaginal and/or perineal approach
	314.01	Attention deficit disorder of childhood with hyperac- tivity		50780	Ureteroneocystostomy; anastomosis of single ureter to bladder
Constipation	307.7	Encopresis		50781	Ureteroneocystostomy
	560.32	Fecal impaction		50782	Ureteroneocystostomy;
	564	Constipation			anastomosis of duplicated
	564.01	Slow transit constipation			ureter to bladder
	564.02	Outlet dysfunction constipa- tion		50783	Ureteroneocystostomy; with extensive ureteral tailoring
	564.09	Other constipation		50785	Ureteroneocystostomy;
	787.6	Full incontinence of feces			with vesico-psoas hitch or bladder flap
Exclusion criteria diagno	ostic codes			50947	Laparoscopy, surgical; ure-
Neurogenic bladder	344.61	Cauda equina syndrome with neurogenic bladder		50947	teroneocystostomy with cystoscopy and ureteral
596.4	596.4	Atony of bladder			stent placement
	596.54	Neurogenic bladder unspecified		50948	Laparoscopy, surgical; uret- eroneocystostomy without
Renal transplant	V42.0	Kidney replaced by trans- plant			cystoscopy and ureteral stent placement

CPT code	Code description	Description	CPT code	Code description
52327	Cystourethroscopy (includ- ing ureteral catheteriza- tion); with subureteric injection of implant material		54324	One stage distal hypospa- dias repair (with or with- out chordee or circumci- sion); with urethroplasty by local skin flaps (e.g.,
50660	Ureterectomy, total, ectopic ureter, combination abdominal, vaginal and/or perineal approach		54326	flip-flap, preputial flap) One stage distal hypospa- dias repair (with or with- out chordee or circumci- sion); with urethroplasty by local skin flaps and mobilization of urethra
51535	Cystotomy for excision, incision, or repair of ureterocele			
52300	Cystourethroscopy; with resection or fulguration of orthotopic ureterocele(s), unilateral or bilateral		54328	One stage distal hypo- spadias repair (with or without chordee or circumcision); with exten-
52301	Cystourethroscopy; with resection or fulguration of ectopic ureterocele(s), unilateral or bilateral			sive dissection to correct chordee and urethroplasty with local skin flaps, skin graft patch, and/or island flap
52400	Incision, destruction, or removal of congenital bladder and bladder canal (urethra) defects using an endoscope		54332	flap One stage proximal penile or penoscrotal hypo- spadias repair requiring extensive dissection to correct chordee and urethroplasty by use of skin graft tube and/or island flap One stage perineal hypo- spadias repair requiring extensive dissection to correct chordee and urethroplasty by use of skin graft tube and/or island flap Repair of hypospadias complications (i.e., fistula, stricture, diverticula); by closure, incision, or exci-
54304	Plastic operation on penis for correction of chordee or for first stage hypospa- dias repair with or without	f chordee hypospa-		
	transplantation of prepuce and/or skin flaps		54336	
54308	Urethroplasty for second stage hypospadias repair (including urinary diver- sion); less than 3 cm			
54312	Urethroplasty for second stage hypospadias repair (including urinary diver- sion); greater than 3 cm		54340	
54316	Urethroplasty for second stage hypospadias repair (including urinary diver- sion) with free skin graft obtained from site other than genitalia		54344	sion, simple Repair of hypospadias complications (i.e., fistula stricture, diverticula); requiring mobilization of skin flaps and urethro-
54318	Urethroplasty for third stage hypospadias repair to release penis from		54348	plasty with flap or patch graft Repair of hypospadias
54322	scrotum (e.g., third stage Cecil repair) One stage distal hypospa- dias repair (with or with- out chordee or circumci- sion); with simple meatal			complications (i.e., fistula stricture, diverticula); requiring extensive dis- section and urethroplasty with, flap, patch or tubed graft (includes urinary
	52327 50660 51535 52300 52301 52301 52400 54304 54308 54312 54316 54318	52327Cystourethroscopy (including ureteral catheterization); with subureteric injection of implant material50660Ureterectomy, total, ectopic ureter, combination abdominal, vaginal and/or perineal approach51535Cystotomy for excision, incision, or repair of ureterocele52300Cystourethroscopy; with resection or fulguration of orthotopic ureterocele(s), unilateral or bilateral52301Cystourethroscopy; with resection or fulguration of ectopic ureterocele(s), unilateral or bilateral52301Cystourethroscopy; with resection or fulguration of ectopic ureterocele(s), unilateral or bilateral52400Incision, destruction, or removal of congenital bladder and bladder canal (urethra) defects using an endoscope54304Plastic operation on penis for correction of chordee or for first stage hypospa- dias repair with or without transplantation of prepuce and/or skin flaps54308Urethroplasty for second stage hypospadias repair (including urinary diver- sion); less than 3 cm54312Urethroplasty for second stage hypospadias repair (including urinary diver- sion); greater than 3 cm54318Urethroplasty for second stage hypospadias repair (including urinary diver- sion); greater than 3 cm54318Urethroplasty for third stage hypospadias repair (including urinary diver- sion) with free skin graft obtained from site other than genitalia54322One stage distal hypospa- dias repair (with or with- out chordee or circumci-	52327 Cystourethroscopy (including ureteral catheterization); with suburcteric injection of implant material 50660 Ureterectomy, total, ectopic ureter, combination abdominal, vaginal and/or perineal approach 51535 Cystotomy for excision, inclision, or repair of ureterocele 52300 Cystourethroscopy; with resection or fulguration of orthotopic ureterocele(s), unilateral or bilateral 52301 Cystourethroscopy; with resection or fulguration of ectopic ureterocele(s), unilateral or bilateral 52400 Incision, destruction, or removal of congenital bladder canal (urethra) defects using an endoscope 54304 Plastic operation on penis for correction of chordee or for first stage hypospadias repair with or without transplantation of prepuce and/or skin flaps 54308 Urethroplasty for second stage hypospadias repair (including urinary diversion); greater than 3 cm 54312 Urethroplasty for second stage hypospadias repair (including urinary diversion); greater than 3 cm 54318 Urethroplasty for second stage hypospadias repair (including urinary diversion); greater than 3 cm 54318 Urethroplasty for second stage hypospadias repair to release penis from second stage hypospadias repair to release penis from second stage hypospadias repair to release penis from second stage hypospadias repair (including urinary diversion); greater than 3 cm 54318 Urethroplasty for steond stage hypospadias repair to release penis from secroture (e.g., third stage Cecii repair)	52327 Cystourethroscopy (includ- ing ureteral catheteriza- tion); with subureteric injection of implant material 54324 50660 Uretercotomy, total, ectopic ureter, combination abdominal, vaginal and/or perineal approach 54326 51535 Cystotomy for excision, incision, or repair of ureteroccle 54328 52300 Cystourethroscopy; with resection or fulguration of orthotopic ureterocele(s), unilateral or bilateral 54328 52400 Incision, destruction, or removal of congenital bladder and bladder canal (urethra) defects using an endoscope 54334 54304 Plastic operation on penis for correction of chordee or for first stage hypospa- dias repair with or without transplantation of prepuce and/or skin flaps 54336 54312 Urethroplasty for second stage hypospadias repair (including urinary diver- sion); less than 3 cm 54340 54312 Urethroplasty for second stage hypospadias repair (including urinary diver- sion) with free skin graft obtained from site other than genitala 54344 54318 Urethroplasty for second stage hypospadias repair (including urinary diver- sion) with free skin graft obtained from site other than genitala 54348 54318 Urethroplasty for third stage hypospadias repair (including urinary diver- sion) with singe meatal 54348

Description	CPT code	Code description
	54352	Repair of hypospadias crip- ple requiring extensive dissection and excision of previously constructed structures including re-release of chordee and reconstruction of urethra and penis by use of local skin as grafts and island flaps and skin brought in as flaps or grafts

Acknowledgements Data for this project were accessed using the Stanford Center for Population Health Sciences Data Core. The PHS Data Core is supported by a National Institutes of Health National Center for Advancing Translational Science Clinical and Translational Science Award (UL1TR003142) and from Internal Stanford funding. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Author contributions KK conceived the study, participated in the design of the study, oversaw data analysis, lead data interpretation, and wrote the manuscript. GA participated in the design of the study, analyzed data, contributed to data interpretation, and wrote the manuscript. RB participated in design of the study, analyzed data and contributed to data interpretation. PV contributed to data interpretation and substantively revised the manuscript. AC analyzed data and contributed to data interpretation. CZ provided feedback and guidance on study design, data analysis, and the manuscript.

Funding Not applicable.

Availability of data and materials The datasets generated and/or analyzed during the current study are not publicly available due to institutional restrictions on data licensing such that this data cannot be made available but the data can be made available upon reasonable request from the corresponding author because our institution prevents us from further access to the Optum data due to change in licensing status across the institution.

Declarations

Conflict of interest The authors declare that they have no competing interests.

Ethical approval and consent to participate The de-identified dataset used in this manuscript is hosted by the Stanford Center for Population Health Sciences. Research on de-identified data hosted by the Stanford Center for Population Health Sciences is conducted under Institutional Review Board (IRB) protocol 40974. This protocol was reviewed by Stanford University's IRB, which falls under the oversight and management of Stanford University's Research Compliance Office (RCO). This protocol includes a waiver of consent, a waiver assent and a waiver of HIPAA authorization. All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki).

Consent for publication Not applicable.

References

- Nevéus T, von Gontard A, Hoebeke P et al (2006) The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol 176(1):314– 324. https://doi.org/10.1016/S0022-5347(06)00305-3
- Vasconcelos MMA, Bastos JM, Arana IE, et al (2020) Association between attention deficit hyperactivity disorder and lower urinary tract symptoms in children and adolescents in a community setting. Int Braz J Urol Off J Braz Soc Urol 47(5):969–978. https:// doi.org/10.1590/S1677-5538.IBJU.2020.0978
- Sampaio C, Sousa AS, Fraga LGA, Veiga ML, Bastos Netto JM, Barroso U (2016) Constipation and lower urinary tract dysfunction in children and adolescents: a population-based study. Front Pediatr. https://doi.org/10.3389/fped.2016.00101
- Özen MA, Mutluer T, Necef I et al (2019) The overlooked association between lower urinary tract dysfunction and psychiatric disorders: a short screening test for clinical practice. J Pediatr Urol 15(4):332.e1-332.e5. https://doi.org/10.1016/j.jpurol.2019.03.025
- Yang S, Chua ME, Bauer S et al (2018) Diagnosis and management of bladder bowel dysfunction in children with urinary tract infections: a position statement from the International Children's Continence Society. Pediatr Nephrol 33(12):2207–2219. https:// doi.org/10.1007/s00467-017-3799-9
- Meena J, Mathew G, Hari P, Sinha A, Bagga A (2020) Prevalence of bladder and bowel dysfunction in toilet-trained children with urinary tract infection and/or primary vesicoureteral reflux: a systematic review and meta-analysis. Front Pediatr. https://doi.org/ 10.3389/fped.2020.00084
- Litwin MS, Saigal CS (eds) (2012) Urologic Diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
- Sureshkumar P, Jones M, Cumming R, Craig J (2008) A population based study of 2,856 school-age children with urinary incontinence. J Urol 181(2):808–815. https://doi.org/10.1016/j.juro.2008.10.044 (discussion 815–816)
- Chung JM, Lee SD, Kang DI et al (2010) An epidemiologic study of voiding and bowel habits in Korean children: a nationwide multicenter study. Urology 76(1):215–219. https://doi.org/10.1016/j. urology.2009.12.022
- Yüksel S, Yurdakul AÇ, Zencir M, Çördük N (2014) Evaluation of lower urinary tract dysfunction in Turkish primary schoolchildren: an epidemiological study. J Pediatr Urol 6(10):1181–1186. https:// doi.org/10.1016/j.jpurol.2014.05.008
- Vaz GT, Vasconcelos MM, Oliveira EA et al (2012) Prevalence of lower urinary tract symptoms in school-age children. Pediatr Nephrol Berl Ger 27(4):597–603. https://doi.org/10.1007/ s00467-011-2028-1
- Bakker E, Van Gool JD, Van Sprundel M, Van Der Auwera C, Wyndaele JJ (2002) Results of a questionnaire evaluating the effects of different methods of toilet training on achieving bladder control. BJU Int 90(4):456–461. https://doi.org/10.1046/j.1464-410x.2002.02903.x
- Sureshkumar P, Craig JC, Roy LP, Knight JF (2000) Daytime urinary incontinence in primary school children: a populationbased survey. J Pediatr 137(6):814–818. https://doi.org/10.1067/ mpd.2000.109196

- Mota DM, Victora CG, Hallal PC (2005) Investigation of voiding dysfunction in a population-based sample of children aged 3 to 9 years. J Pediatr (Rio J) 81:225–232. https://doi.org/10.1590/ S0021-75572005000400009
- Ozçetin M, Uluocak N, Yılmaz R et al (2010) Evaluation of urinary incontinence in preschool children. J Dent Child 9(2):75–81
- Schäfer SK, Niemczyk J, von Gontard A, Pospeschill M, Becker N, Equit M (2018) Standard urotherapy as first-line intervention for daytime incontinence: a meta-analysis. Eur Child Adolesc Psychiatry 27(8):949–964. https://doi.org/10.1007/ s00787-017-1051-6
- Ozden C, Ozdal OL, Altinova S, Oguzulgen I, Urgancioglu G, Memis A (2007) Prevalence and associated factors of enuresis in Turkish children. Int Braz J Urol Off J Braz Soc Urol 33(2):216– 222. https://doi.org/10.1590/s1677-55382007000200013
- Gür E, Turhan P, Can G et al (2004) Enuresis: prevalence, risk factors and urinary pathology among school children in Istanbul, Turkey. Pediatr Int Off J Jpn Pediatr Soc 46(1):58–63. https://doi. org/10.1111/j.1442-200X.2004.01824.x
- van den Berg MM, Benninga MA, Di Lorenzo C (2006) Epidemiology of childhood constipation: a systematic review. Off J Am Coll Gastroenterol ACG 101(10):2401–2409
- Benninga MA, Buller HA, Heymans HS, Tytgat GN, Taminiau JA (1994) Is encopresis always the result of constipation? Arch Dis Child 71:186–193
- De Paepe H, Renson C, Van Laecke E, Raes A, Vande Walle J, Hoebeke P (2000) Pelvic-floor therapy and toilet training in young children with dysfunctional voiding and obstipation. BJU

- Liem O, Harman J, Benninga M, Kelleher K, Mousa H, Di Lorenzo C (2009) Health utilization and cost impact of childhood constipation in the United States. J Pediatr 154(2):258–262. https://doi.org/10.1016/j.jpeds.2008.07.060
- Thomas R, Sanders S, Doust J, Beller E, Glasziou P (2015) Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics 135(4):e994–e1001. https:// doi.org/10.1542/peds.2014-3482
- Joinson C, Heron J, von Gontard A (2006) Psychological problems in children with daytime wetting. Pediatrics 118(5):1985–1993. https://doi.org/10.1542/peds.2006-0894
- Jensen ET, Cook SF, Allen JK et al (2015) Enrollment factors and bias of disease prevalence estimates in administrative claims data. Ann Epidemiol 25(7):519-525.e2. https://doi.org/10.1016/j.annep idem.2015.03.008

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.